The pandemic has changed society profoundly. The disruption in human and business interactions have not only affected the travel, conference, and hospitality industries but has also changed the clinical research landscape forever.
With the rush for vaccines, we are seeing pharmas and biotechs perform virtual clinical trials, Real World Evidence (RWE), patient visits, study enrollment, and clinical outcome assessments (COAs) almost exclusively virtually. This has accelerated the adoption of electronic patient data capture; both self- and clinician-reported. The rapidity of study startup and necessary documentation required has made clinical services companies address their models and create new technologies to meet the new normal.
While the pandemic has unleashed on the world never-before-seen challenges, it’s worth noting the positive outcomes as well. Large pharma and biotech companies have collaborated to develop a vaccine in record-breaking time without sacrificing any of the safety protocols prescribed by the notifying bodies. Life science technology vendors have seen a paradigm shift in the adoption of patient data gathered electronically. There is an increased demand for app-based solutions, and those deployed solutions have been updated at a faster rate than ever before seen.